ArticleJournal of clinical psychopharmacology
RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.
Article in Journal of clinical psychopharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03062033 (Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.Frontiers in neurology · 2024Pooled it
- Schizophrenia and disordered sensorimotor control: challenges, mechanisms and opportunities.Brain : a journal of neurology · 2026Review
- Living with tardive dyskinesia: understanding the patient experience.CNS spectrums · 2026Review
- Aripiprazole or Bupropion Augmentation Versus Switching to Bupropion in Treatment-Resistant Depression: A Risk-Benefit Analysis.The Journal of clinical psychiatry · 2025Article
- Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review.European psychiatry : the journal of the Association of European Psychiatrists · 2025Review
- Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data.BMC psychiatry · 2025Article
- Patient and physician perceptions of the burden of tardive dyskinesia: an international survey.BMJ neurology open · 2025Article
- Article
- Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database.Frontiers in pharmacology · 2024Article
- Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States.Journal of patient-reported outcomes · 2023Article
- Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review.The mental health clinician · 2023Article
- The Outcome of Antipsychotics-induced Tardive Syndromes: A Ten-year Follow-up Study.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Telehealth for Assessing and Managing Tardive Dyskinesia: Expert Insights from a Cross-Disciplinary Virtual Treatment Panel.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023Article
- Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.Journal of patient-reported outcomes · 2023Article
- Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications.Frontiers in psychiatry · 2023Article
- Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan.Therapeutic advances in psychopharmacology · 2022Review
- Patient perspective of tardive dyskinesia: results from a social media listening study.BMC psychiatry · 2021Article
- Tardive Dyskinesia in Older Persons Taking Antipsychotics.Neuropsychiatric disease and treatment · 2021Review
- Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations.Neuropsychiatric disease and treatment · 2021Review
- Recent Advances in the Pharmacology of Tardive Dyskinesia.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PURPOSE/
backgroundRE-KINECT (NCT03062033) was designed to assess the presence and impact of possible tardive dyskinesia (TD) in antipsychotic-treated outpatients. METHODS/PROCEDURES: The study included adults with 3 or more months of lifetime antipsychotic exposure and 1 or more psychiatric disorder. Based on clinician observation and assessment, patients were assigned to cohort 1 (without involuntary movements or with non-TD involuntary movements) or cohort 2 (with involuntary movements confirmed by clinician as possible TD). Baseline assessments included the following: patient characteristics; location/severity of involuntary movements; and impact of possible TD on health-related quality of life, including the EuroQoL 5-Dimensions 5-Level questionnaire. FINDINGS/
resultsOf 739 eligible patients, 204 (27.6%) had clinician-confirmed possible TD (cohort 2). Compared with cohort 1, patients in cohort 2 were significantly older (P < 0.0001), more likely to have schizophrenia or schizoaffective disorder (P < 0.0001) and longer lifetime exposure to antipsychotics (P < 0.0001), and less likely to be working or studying, based on clinician perception (P = 0.0010). Clinician- and patient-rated severity of possible TD movements was significantly correlated in each of 4 body regions (head/face, neck/trunk, upper extremities, lower extremities), for maximum severity in any region, and for total number of affected regions (P < 0.001 for all correlations). For the patient-rated EuroQoL 5-Dimensions 5-Level, the health state visual analog scale score was significantly lower (worse) in cohort 2 versus cohort 1 (66.8 vs 69.7; P = 0.0002), as was the utility index score (0.71 vs 0.76; P < 0.0175). IMPLICATIONS/
conclusionsResults from this real-world population indicate that TD occurs frequently and can significantly reduce quality of life in patients with a psychiatric disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.